CRC cell lines with naturally high AMPKα1 activity showed greater vulnerability to metformin’s effects, suggesting that pre-existing high AMPK status, or markers reflecting its activity, could be a potential predictive biomarker for stratifying patients and identifying those likely to respond positively to metformin’s activation of AMPK. Here, PRKAA1 is linked to colorectal carcinoma.